Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

  • Name

    Regeneron Pharmaceuticals, Inc.

  • CEO

    Dr. Leonard S. Schleifer M.D., Ph.D.

  • Website

    www.regeneron.com

  • Sector

    Biotechnology

  • Year Founded

    1988

Profile

  • Market Cap

    $123.2B

  • EV

    $108.37B

  • Shares Out

    107.93M

  • Revenue

    $13.49B

  • Employees

    13,926

Margins

  • Gross

    53.27%

  • EBITDA

    33.5%

  • Operating

    30.14%

  • Pre-Tax

    34.01%

  • Net

    32.04%

  • FCF

    24.68%

Returns (5Yr Avg)

  • ROA

    21.11%

  • ROTA

    29.42%

  • ROE

    29.19%

  • ROCE

    26.65%

  • ROIC

    30.74%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $1,162.19

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $9,809M

  • Net Debt

    -$14.83B

  • Debt/Equity

    0.1

  • EBIT/Interest

    60.69

Growth (CAGR)

  • Rev 3Yr

    2.89%

  • Rev 5Yr

    15.57%

  • Rev 10Yr

    18.37%

  • Dil EPS 3Yr

    -11.97%

  • Dil EPS 5Yr

    15.97%

  • Dil EPS 10Yr

    26.59%

  • Rev Fwd 2Yr

    8.24%

  • EBITDA Fwd 2Yr

    5.54%

  • EPS Fwd 2Yr

    5.65%

  • EPS LT Growth Est

    19%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:REGN